Monoclonal Antibody Infusion is a therapy granted by the FDA’s Emergency Use Authorization (EUA) as a treatment for severe COVID-19 symptoms in patients at high risk of hospitalization.
Monoclonal Antibody Infusion is available now for patients who meet the following requirements:
You have a positive COVID-19 test result
You are not already hospitalized
You have mild-to-moderate symptoms that started less than 10 days ago
You have certain medical conditions or other health factors that place you at a higher risk of progressing to a severe infection:
Age 65 years or older
Obese or over weight which may include a Body Mass Index (BMI) of 25 or higher for adults or a BMI in the 85th percentile or higher on the growth chart for pediatric patients.
Pregnant
Diabetes
Chronic kidney disease
Immunosuppressive disease, or on immunosuppressive treatment
Cardiovascular disease (including congenital heart disease) or hypertension
Chronic lung disease such as chronic obstructive pulmonary disease (COPD), moderate to severe asthma, cystic fibrosis, or pulmonary hypertension)
Leave a Reply